Hydralazine in Heart Failure with Reduced Ejection Fraction
Hydralazine combined with isosorbide dinitrate (H-ISDN) should be prescribed for self-identified Black or African American patients with HFrEF (LVEF ≤40%) who have NYHA class III-IV symptoms despite optimal therapy with ACE inhibitors/ARBs/ARNI and beta-blockers, as this combination reduces mortality by 43% in this population. 1, 2
Primary Indication: Self-Identified Black or African American Patients
The 2022 ACC/AHA guidelines provide a Class I recommendation for adding H-ISDN to standard GDMT (ACEi/ARB/ARNI plus beta-blocker) in self-identified Black or African American patients with symptomatic HFrEF (NYHA class III-IV). 3
This recommendation is based on the African-American Heart Failure Trial (A-HeFT), which demonstrated a 43% reduction in mortality when H-ISDN was added to contemporary guideline-based therapy in Black patients with advanced heart failure. 4, 5
The 2020 ACC/AHA performance measures specifically track prescribing of H-ISDN in this population as a quality metric, emphasizing that this therapy remains significantly underutilized despite strong evidence. 1, 2
Secondary Indication: ACE Inhibitor/ARB/ARNI Intolerance
H-ISDN serves as an alternative when renin-angiotensin system inhibitors cannot be used due to intolerance (such as angioedema, severe hyperkalemia, or renal dysfunction) or contraindications. 6, 5
The 1995 ACC/AHA guidelines established H-ISDN as a Class I recommendation for patients who cannot tolerate ACE inhibitors, based on the original V-HeFT I trial showing 34% mortality reduction at 2 years. 7, 5
The 2016 ESC guidelines include H-ISDN in their treatment algorithm specifically for patients where ACE inhibitors, ARBs, or ARNI are not tolerated or contraindicated. 6
Mechanism and Hemodynamic Effects
Hydralazine acts as a direct arterial vasodilator by relaxing vascular smooth muscle through interference with calcium metabolism, resulting in decreased afterload and increased cardiac output. 8
Isosorbide dinitrate provides venous vasodilation and improves nitric oxide bioavailability, reducing preload and left ventricular wall tension. 9
The combination decreases left ventricular end-diastolic diameter, reduces mitral regurgitation volume, lowers pulmonary artery pressures, and induces left ventricular reverse remodeling. 9
Hydralazine specifically mitigates nitrate tolerance that develops with continuous isosorbide dinitrate use, maintaining therapeutic efficacy during long-term treatment. 4, 10
Dosing and Titration
Target dosing is hydralazine 75 mg three times daily plus isosorbide dinitrate 40 mg three times daily, as used in the A-HeFT trial. 4
Start with lower doses (hydralazine 25 mg three times daily plus isosorbide dinitrate 20 mg three times daily) and titrate upward based on blood pressure tolerance and symptom response. 11
A fixed-dose combination formulation is available, which may improve adherence compared to separate medications. 4
Important Caveats and Monitoring
Hydralazine undergoes polymorphic acetylation, meaning slow acetylators have higher plasma levels and may require lower doses to avoid side effects like headache, tachycardia, and hypotension. 8
Monitor for drug-induced lupus syndrome with long-term hydralazine use, particularly at doses >200 mg daily and in slow acetylators. 8
Reflex tachycardia from hydralazine increases myocardial oxygen demand; ensure adequate beta-blocker therapy is established before initiating H-ISDN. 12
Nitrate tolerance can develop despite hydralazine co-administration; if symptoms worsen after initial improvement, consider dose adjustment or alternative therapies. 10
Clinical Context and Underutilization
H-ISDN remains significantly underused in eligible Black patients, with studies showing prescription rates well below 50% even in those meeting guideline criteria. 5
The combination is often overlooked due to three-times-daily dosing complexity, side effects (particularly headache from nitrates), and polypharmacy concerns in patients already on multiple HF medications. 10
Despite being superseded by ACE inhibitors, ARBs, and ARNI as first-line therapy in non-Black populations, H-ISDN fills a critical gap for Black patients who have persistently higher HF mortality rates even on standard GDMT. 5
The 2022 ACC/AHA guidelines position H-ISDN as part of comprehensive quadruple therapy for HFrEF, which can extend life expectancy by approximately 6 years compared to dual therapy alone. 13
When NOT to Use Hydralazine-Isosorbide Dinitrate
Do not use in patients with severe hypotension (systolic BP <90 mmHg) or those unable to tolerate vasodilator therapy. 11
Avoid in patients with severe aortic stenosis, as afterload reduction can precipitate hemodynamic collapse. 12
Use caution in patients with coronary artery disease, as reflex tachycardia may precipitate myocardial ischemia despite improved hemodynamics. 12